Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 5Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia 3Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Craniopharyngioma 2COVID-19 2Burkitt Lymphoma 2Arthritis, Rheumatoid 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Pancreatic Carcinoma 1Triple Negative Breast Neoplasms 1Stroke 1Sarcoma 1Respiratory Tract Infections 1Recurrence 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Ribavirin 2tocilizumab 1Thoracoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Respiratory Tract Infections × tocilizumab × Clear all
NCT04377659 2025-05-28

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
9 enrolled 8 charts

COVID-19, Respiratory Tract Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡